Page 107 - MEMORIA ANUAL 2018 SEHH-FEHH

MEMORIA ANUAL 2018
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
• García-Gutiérrez V, Milojkovic D, Hernández-Boluda JC, Claudiani S, Martín Mateos ML, Casado-Montero LF, González G, Jiménez-Velasco A, Boque C, Martínez-Trillos A, Vázquez IM, Payer ÁR, Senín A, Amustio Díez E, García AB, Carras- cosa GB, Ortí G, Ruiz BC, Fernández MÁ, Del Carmen García Garay M, Giraldo P, Guinea JM, De Las Heras Rodríguez N, Hernán N, Pérez AI, Piris-Villaespesa M, Lorenzo JLL, Martí-Tutusaus JMM, Vallansot RO, Ortega Rivas F, Puerta JM, Ramírez MJ, Romero E, Romo A, Rosell A, Saavedra SS, Sebrango A, Tallon J, Valencia S, Portero A, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. Ann Hematol. 2019 Feb;98(2):321-30. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16.
• Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarría E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF. Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2018 Jan;144(1):187-8. doi: 10.1007/s00432-017-2532-1.
Presentaciones en congresos internacionales
• 23rd European Hematology Association (EHA) Congress. Stockholm, Sweden, June 14-17, 2018:
– Alonso-Domínguez JM, Olavarría E, Pérez Encinas M, de Paz Arias R, Ayala Díaz RM, Casado Montero LF, Ferrer Marín F, Bautista Carrascosa G, Conesa García V, Mba C, Steegmann JL. Update of CMRegistry: an observational, multi- center, prospective follow-up registry of patients with chronic phase CML with a high probability of obtaining a stable deep molecular response >MR4 (IS).
– Gómez-Centurión I, Osorio Prendes S, Escudero Vilaplana V, Pérez-López R, Ayala R, Vall-Llovera F, García-Gutiérrez V, Gómez Casares MT, González San Miguel JD, Hernández-Rivas JA, Sánchez-Guijo F, Romera M, Villalón L, Conesa V, Rodríguez A, Casado F, Sáez Perdomo MN, Baños U, Díez-Martín JL, Steegmann JL. An approach to drug-to-drug interactions in CML patients treated with tyrosine kinase inhibitors. An observational study of the Spanish CML Group (GELMC). EHA Learning Center. Gómez-Centurión I. Jun 14, 2018; 216313.
• American Society of Hematology (ASH) 2018, 60th Annual Meeting and Exposition. December 1-4, 2018, San Diego, CA:
– Hernández-Boluda JC, Pereira A, Pastor-Galán I, Álvarez-Larrán A, Savchuk A, Puerta JM, Sánchez-Pina JM, Collado R, Díaz-González A, Angona A, Sagüés M, García-Gutiérrez V, Boqué C, Osorio S, Vallansot R, Palomera L, Mendizábal A, Casado LF, Pérez-Encinas M, Pérez-López R, Ferrer-Marín F, Sánchez-Guijo F, García C, Heras NL, López-Lorenzo JL, Cervantes F, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). Feasibility of treatment dis- continuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
GRUPO ESPAÑOL DE LEUCEMIA MIELOIDE CRÓNICA (GELMC)
107